The Department of Justice (DOJ) has modified its emergency scheduling framework for specific kratom-derived opioids after evaluating new research from the Department of Health and Human Services (HHS). These adjustments target 7-hydroxymitragynine, often referred to as 7-OH, alongside mitragynine pseudoindoxyl (MGPI) and two synthetic compounds, MGM-15 and MGM-16.
Federal officials explained that the updated strategy aims to target products with raised levels of these compounds while still recognizing the trace amounts that naturally appear in botanical kratom.
Revised Guidelines
The DEA intends to release two fresh emergency scheduling frameworks, referred to as Notices of Intent, within the revised process. These documents outline the agency’s proposed measures and provide the public with details regarding the anticipated modifications.
The revisions follow new scientific information and recommendations from HHS concerning the presence and concentration of certain opioid substances in kratom-related products. One major change involves 7-OH and MGPI. It recommended new limits based on the amount of these substances found in solid and liquid products.
Controls and Limits
According to the recommendation, Schedule I regulations would be triggered when the concentration of either compound alone, or the total when both are present, surpasses one milligram per gram in solid formulations or one milligram per milliliter in liquid formulations. Additionally, controls would apply if the proportion of mitragynine to 7-OH, MGPI, or their combined quantity drops below 100 to 1.
Read Also: Illinois Woman Gets 31 Months for Monkey Torture Videos
These thresholds are designed to assist federal authorities in differentiating between products containing naturally occurring compounds and those that have been artificially enhanced with higher concentrations. The updated analysis emphasizes that 7-OH can naturally occur in botanical kratom, albeit typically in minimal amounts.
It also reported that new scientific information suggests MGPI may be present in trace amounts in some botanical or kratom-derived products. Researchers are still learning more about MGPI and its presence in kratom-related products.
Next Steps
For MGM-15 and MGM-16, the DEA is adopting an alternative strategy. Within its emergency scheduling framework, the agency intends to reissue its Notice of Intent for these two compounds without modifying the current scheduling methodology. Attorney General Todd Blanche stated that the department’s initiatives aimed to safeguard children and communities from harmful and habit-forming substances.
Federal officials also linked this initiative to their wider efforts combating drug trafficking and the distribution of potent synthetic drugs. The announcement does not imply that all kratom-containing products will automatically face identical restrictions. Future actions will depend on the DEA’s revised notices and any resulting scheduling directives.
